独特のアルツハイマー病のβ-アミロイド三角線維は,生理学的条件下で線維軸に沿って空洞を持っています
Yifat Miller1, Buyong Ma, Ruth Nussinov
1Center for Cancer Research Nanobiology Program NCI-Frederick, Frederick, Maryland 21702, USA.
Journal of the American Chemical Society
|February 9, 2011
まとめ
アルツハイマー病の研究は,Aβ1-40) 線維細胞構造を明らかにし,中央腔と線維細胞軸に沿ったM35相互作用を特定し,治療設計に不可欠です.
科学分野:
- バイオケミストリー バイオケミストリー
- 神経科学は神経科学である.
- 構造生物学 構造生物学とは
背景:
- アルツハイマー病 (AD) 研究は,アミロイドベータ (Aβ) 線維に重点を置いています.
- Aβ1-40) 線維の構造を理解することは,初期段階の治療法の開発の鍵です.
- メチオニン35 (M35) は,酸化可能性とAβ繊維内の相互作用により重要な残留物です.
研究 の 目的:
- 完全な長さのAβ ((1-40)) 線維の三重対称コンフォマーを調査する.
- Aβ繊維の構造におけるM35相互作用の役割を明確にするために.
- Aβ ((1-40)) 線維細胞形成の構造的基礎と潜在的な治療標的の解明.
主な方法:
- 明確な溶媒での全原子分子ダイナミクスシミュレーション.
- 実験的な固体NMR (ssNMR) データの分析.
- 残基間の距離の構造的解釈 (M35-M35,I31-V39) について.
主要な成果:
- シミュレーションは実験的な距離M35-M35とI31-V39を再現した.
- M35-M35の相互作用は,主に線維軸に沿って発生し,それを越えて (>15 Å) 発生しません.
- Aβ(1-40) 線維は,大きな軸腔を持つ三角形の構造を示し,N-端の相互作用を安定させる.
結論:
- Aβ ((1-40)) 線維構造は,以前のモデルとは異なる軸腔を特徴としています.
- 線維軸に沿ったM35の相互作用は,線維の安定性にとって有意である.
- Aβ ((1-40/1-42) オリゴマーの特定された空洞は,アルツハイマー病におけるオリゴマーの毒性を理解し,標的化するために重要である.
関連する概念動画
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Protein Folding
Overview
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

